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Background: Limited evidence exists on the impact of adding a taxane, using
endocrine therapy and carrying a deleterious germline BRCAmutation on ovarian reserve
measured by anti-müllerian hormone (AMH) levels of young breast cancer patients
receiving (neo)adjuvant cyclophosphamide- and anthracycline-based chemotherapy.
Methods: This is a biomarker analysis including young (≤40 years) early breast cancer
patients with known germline BRCA mutational status and available prospectively
collected frozen plasma samples before and after chemotherapy. Chemotherapy
consisted of either six cycles of FEC (5 fluorouracil 500 mg/m2, epirubicin 100 mg/m2,
cyclophosphamide 500 mg/m2) or three cycles of FEC followed by three cycles of
docetaxel (D, 100 mg/m2). Endocrine therapy consisted of tamoxifen (±GnRH agonists).
AMH levels at baseline, 1 and 3 years after diagnosis were compared according to
type of chemotherapy (FEC only vs. FEC-D), use of endocrine therapy (yes vs. no) and
deleterious germline BRCA mutations (mutated vs. negative).
Results: Out of 148 included patients, 127 (86%) received D following FEC
chemotherapy, 90 (61%) underwent endocrine therapy, and 35 (24%) had deleterious
germline BRCA mutations. In the whole cohort, AMH levels drastically dropped 1 year
after diagnosis (p < 0.0001) with a slight but significant recovery at 3 years (p < 0.0001).
Lambertini et al. Gonadotoxicity of Breast Cancer Treatments
One year after diagnosis, patients treated with FEC only had higher median AMH levels
than those who received FEC-D (0.22 vs. 0.04 µg/L, p = 0.0006); no difference was
observed at 3 years (0.06 and 0.18 µg/L, p = 0.47). Patients under endocrine therapy
had significantly higher AMH levels than those who did not receive this treatment 1
year after diagnosis (0.12 vs. 0.02 µg/L; p = 0.008), with no difference at 3 years
(0.11 and 0.20 µg/L, p = 0.22). AMH levels were similar between BRCA-mutated and
BRCA-negative patients at baseline (1.94 vs. 1.66 µg/L, p = 0.53), 1 year (0.09 vs. 0.06
µg/L, p = 0.39) and 3 years (0.25 vs. 0.16 µg/L; p = 0.43) after diagnosis.
Conclusions: In breast cancer patients receiving FEC chemotherapy, adding
D appeared to negatively impact on their ovarian reserve in the short-term; no further
detrimental effect was observed for endocrine therapy use and presence of a deleterious
germline BRCA mutation.
Keywords: breast cancer, AMH, taxane, endocrine therapy, BRCA mutations
INTRODUCTION
As a consequence of the higher incidence of aggressive tumor
subtypes and the negative prognostic value of young age at
diagnosis (1, 2), a significant proportion of young women
with early breast cancer are candidates to receive adjuvant or
neoadjuvant chemotherapy. In young patients, a major potential
drawback associated with the use of systemic cytotoxic therapy
is represented by the risk of causing gonadal damage with
subsequent premature ovarian insufficiency (POI) and infertility
(3). Considering the substantial quality of life implications
associated with the development of these side effects, appropriate
oncofertility counseling is now considered mandatory with all
cancer patients diagnosed during their reproductive years (4–6).
Age and use of cyclophosphamide-based chemotherapy
are the two major known determinants influencing the
risk of gonadal damage following the use of anticancer
treatments in young women with breast cancer (3). On the
contrary, the impact of other treatment- or patient-related
factors remains controversial. Specifically, while the effect
of cyclophosphamide- and anthracycline-based chemotherapy
regimens is well-established, it remains unclear if the addition
of a taxane can further increase the risk of gonadal damage
(7). Similarly, in young patients with hormone receptor-positive
disease, the gonadotoxic impact of using endocrine therapy
following chemotherapy remains debated (7, 8). Finally, recent
evidence suggests that carrying a deleterious germline BRCA
mutation may have a negative impact on women ovarian
reserve raising the important concern of a potential increased
gonadotoxicity with the use of anticancer treatments in this
patient population (9, 10).
Informing young women with newly diagnosed breast
cancer about the actual gonadal damage associated with the
use of the proposed anticancer treatments is even more
complex considering that the majority of the studies that
addressed this issue relied only on the presence or absence
of menstrual function after the end of chemotherapy (3).
However, this cannot be considered a surrogate to determine
treatment-induced gonadotoxicity (11). Being the most accurate
indicator of remaining ovarian reserve, anti-müllerian hormone
(AMH) is considered a promising biomarker of treatment-
induced gonadotoxicity (12). Nevertheless, to date, there is
limited evidence on the actual gonadal damage associated
with the use of the proposed anticancer treatments through
AMH assessment in young breast cancer patients (12). This
is crucial information to be acquired to better inform
these patients about the adverse events associated with the
proposed therapies as well as on the need of pursuing fertility
preservation strategies before treatment initiation. To acquire
more insights on this unmet medical issue, we conducted
the present study aiming to evaluate the impact of adding
a taxane, using endocrine therapy as well as carrying a
deleterious germline BRCA mutation on the ovarian reserve
measured by AMH levels at baseline and up to 3 years
after diagnosis in young early breast cancer patients treated




This is a biomarker analysis conducted within a cohort of
consecutive patients with early breast cancer diagnosed at ≤40
years that underwent (neo)adjuvant chemotherapy between
January 2008 and December 2016 at the Henri Becquerel Cancer
Center (Rouen, France). Patients with known germline BRCA
mutational status and prospectively collected and available frozen
plasma samples before and after chemotherapy were eligible for
inclusion in the present analysis.
Chemotherapy consisted of either six cycles of FEC
(five fluorouracil 500 mg/m2, epirubicin 100 mg/m2,
cyclophosphamide 500 mg/m2) or three cycles of FEC followed
by three cycles of docetaxel (D, 100 mg/m2). Adjuvant endocrine
therapy consisted of tamoxifen exclusively or associated with
gonadotropin-releasing hormone (GnRH) agonists. None of
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FIGURE 1 | The flow diagram of participants. GnRHa, gonadotropin-releasing hormone agonists.
the patients received GnRH agonists during chemotherapy for
ovarian function and/or fertility preservation.
All patients signed a consent form allowing the conservation
and study of their biological samples. The present study was
approved by the Institutional Scientific and Ethics Committees
of Henri Becquerel Centre (registering order N◦1807B).
AMH Measurements
As per routine practice at our center, plasma samples are
prospectively collected at fixed timepoints during follow-up in
all breast cancer patients and are stored in our plasma bank
at−20◦C.
For the purpose of the present analysis, plasma samples of
eligible patients were used to assess AMH levels at baseline
(i.e., before starting chemotherapy), ∼1 year and over 3 years
after diagnosis.
AMH measurements were centrally performed at Henri
Becquerel Cancer Center using fully automated ultra-sensitive
Elecsys AMH assay on the Cobas e601 instrument (Roche
Diagnostics). The detection and quantification limits were 0.01
and 0.03 µg/L, respectively, with an intra-assay imprecision
coefficient of variation equal to 1.2% at 1.19 µg/L and 0.9% at
5.89 µg/L.
Study Objectives
The main objective of this study was to assess the impact of
adding a taxane (D), using endocrine therapy and carrying a
deleterious germline BRCA mutation on the ovarian reserve
measured by AMH levels of young breast cancer patients
after (neo)adjuvant cyclophosphamide- and anthracycline-
based chemotherapy (FEC). AMH levels at baseline, 1 and
3 years after diagnosis were compared according to type
of chemotherapy (FEC only vs. FEC-D), use of endocrine
therapy (yes vs. no) and deleterious germline BRCA mutations
(mutated vs. negative).
Statistical Analysis
Baseline characteristics of patients were compared according to
type of chemotherapy or endocrine treatment administered and
BRCA mutational status. Quantitative variables were reported
as median with interquartile range (IQR, Q1–Q3). Differences
were tested using χ2, Fisher’s exact test or two-sample t-tests
as appropriate.
Comparisons of the evolution of AMH values over time were
restricted to the same patients, using paired tests (Wilcoxon).
A p-value of <0.05 was considered statistically significant.
Tests were performed using the R R© statistical software version




Between January 2008 and December 2016, out of 262
patients diagnosed at ≤40 years who underwent (neo)adjuvant
chemotherapy for early breast cancer, 148 had plasma samples
and BRCA mutational status available to be included in the
present analysis (Figure 1).
Median age was 35 years (IQR 31.5–38; Table 1). A total of
127 (86%) patients received D in addition to FEC chemotherapy,
90 (61%) underwent endocrine therapy, and 35 (24%) had
deleterious germline BRCAmutations.
AMH Evolution Under Chemotherapy in the
Whole Population
At baseline, median AMH level was 1.68 µg/L (IQR 1.00–3.30).
Higher age was associated with significant lower AMH levels
(p= 0.047; Figure S1).
One year after diagnosis (median 387 days, IQR 363–426),
AMH levels drastically dropped to a median value of 0.06 µg/L
(IQR 0–0.25; p < 0.0001). Three years after diagnosis (median
1,132 days, IQR 1,099–1,186), a slight but significant recovery of
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TABLE 1 | Baseline patients’ and tumor characteristics.
Patient characteristics All patients (n = 148)
Age at diagnosis, median [IQR] 35.5 [31.5–38]
AMH, median [IQR] 1.68 [1.00–3.30]
AMH, mean [SD] 2.55 [2.81]
Body mass index (kg/m²), median [IQR] 22.7 [21.0–26.2]
Smoker, n (%) 52 (35%)
Genetic mutation, n (%) 35 (24%)
BRCA1 22 (63%)
BRCA2 13 (37%)
Tumor characteristics, n (%)
Histological grade
Grade I 6 (4%)
Grade II 54 (36%)
Grade III 87 (59%)
Not available 1 (<1%)
Hormone receptor positivity 92 (62%)
Oestrogen receptor 90 (61%)
Progesteron receptor 65 (44%)
HER2-positive 27 (18%)
Triple-negative 52 (35%)






Surgical treatment, n (%)
Conservative 82 (55%)
Mastectomy 66 (45%)
Adjuvant treatment, n (%)
Radiation therapy 144 (97%)
Endocrine therapya 90 (61%)
Chemotherapy 148 (100%)
Chemotherapy regimen, n (%)
3 FEC−3 D 127 (86%)
6 FEC 21 (14%)
Endocrine therapy, n (%)
Tamoxifen 82 (91%)
Tamoxifen + GnRH agonists 8 (9%)
Fertility history, n (%)
Pregnancy before treatment 129 (84%)
Childbirth before treatment 128 (84%)
a2 patients with hormone receptor-positive tumors refused endocrine therapy.
AMH, anti-mullerian hormone; IQR, interquartile range; SD, standard deviation; FEC,
fluorouracil, epirubicin, cyclophosphamide; D, docetaxel; GnRH, gonadotropin-releasing
hormone.
AMH value was observed with a median level of 0.17 µg/L (IQR
0.04–0.41; p < 0.0001; Figure S2).
Impact of Taxanes
Baseline characteristics according to type of chemotherapy (FEC
only vs. FEC-D) are reported in Table S1.
At baseline, no difference in AMH levels was observed
between patients treated with FEC only (1.66 µg/L, IQR 1.06–
2.85) or FEC-D (1.69 µg/L, IQR 0.98–3.33; p= 0.83) (Figure 2).
One year after diagnosis, patients treated with FEC only
had higher median AMH levels (0.22 µg/L, IQR 0.10–0.36) as
compared to those who received FEC-D (0.04 µg/L, IQR 0.00–
0.21; p= 0.0006), respectively.
Three years after diagnosis, no difference in median AMH
levels was observed between patients treated with FEC only
(0.06 µg/L, IQR 0.04–0.32) or FEC-D (0.18 µg/L, IQR 0.04–
0.43; p = 0.47). Patients treated with FEC only had no recovery
of AMH values between 1 and 3 years (0.22 vs. 0.06 µg/L,
respectively, p = 0.81) while patients treated by FEC-D had a
slight but significant recovery (0.04 vs. 0.18 µg/L, p < 0.0001).
Impact of Endocrine Therapy
Baseline characteristics according to use of endocrine therapy
(yes vs. no) are reported in Table S2. Among the 90 (61%)
patients who received endocrine therapy, 82 (91%) underwent
tamoxifen alone and 8 (9%) tamoxifen combined with GnRH
agonists (Table 1). At the 3-year timepoint, all but three patients
who started endocrine therapy were still under treatment.
At baseline, no difference in AMH values was observed
between patients who received endocrine therapy (1.94 µg/L,
IQR 1.01–3.76) and those who did not (1.50µg/L, IQR 0.96–2.77;
p= 0.17) (Figure 3).
One year after chemotherapy, patients under endocrine
therapy had significantly higher AMH levels (0.12 µg/L, IQR
0.02–0.29) than those who did not receive this treatment (0.02
µg/L, IQR 0.00–0.12; p= 0.008).
No difference was observed 3 years after diagnosis, with
comparable values of AMH for patients undergoing endocrine
therapy (0.11 µg/L, IQR 0.03–0.43) or not (0.20 µg/L, 0.07–0.40;
p= 0.22).
Impact of Carrying a Deleterious Germline
BRCA Mutation
Baseline characteristics according to BRCA mutational status
(mutated vs. negative) are reported in Table S3. Among the 35
(24%) BRCA-mutated breast cancer patients, 22 and 13 harbored
deleterious BRCA1 or BRCA2 mutations, respectively. Patients
in the BRCA-mutated cohort were younger than those without
mutation (p= 0.027).
At baseline, no difference in AMH values was observed
between BRCA-mutated (1.94 µg/L, IQR 0.98–3.96) and BRCA-
negative (1.66 µg/L, IQR 1.00–3.02) patients (p = 0.53)
(Figure 4).
One year after chemotherapy, AMH values drastically
dropped in both groups to 0.09 µg/L (IQR 0.00–0.30) and
0.06 µg/L (IQR 0.00–0.21) in the BRCA-mutated and negative
cohorts, respectively (p= 0.39).
Recovery at 3 years from diagnosis was observed in a similar
extent in both groups with levels of 0.25 µg/L (IQR 0.02–
0.95) and 0.16 µg/L (IQR 0.04–0.39) in the BRCA-mutated and
negative cohorts, respectively (p= 0.43).
When the analyses were repeated to take into account the
different age at diagnosis, similar results were shown with no
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FIGURE 2 | The evolution of anti-mullerian hormone levels according to type of chemotherapy. *Statistical significant difference. AMH, anti-mullerian hormone; CT,
chemotherapy; FEC, fluorouracil, epirubicin, cyclophosphamide; D, docetaxel.
FIGURE 3 | The evolution of anti-mullerian hormone levels according to use of endocrine therapy. *Statistical significant difference. AMH, anti-mullerian hormone; ET,
endocrine therapy.
difference in AMH levels between the BRCA-mutated and the
BRCA-negative cohorts both at diagnosis and after treatment
(Supplementary Data). Similarly, within the BRCA-mutated
cohort, no impact of the type of BRCA mutation (BRCA1 vs.
BRCA2) was observed (Figure S3).
DISCUSSION
In this study, we assessed the ovarian reserve measured by AMH
levels at baseline and up to 3 years after diagnosis in young early
breast cancer patients treated with (neo)adjuvant anthracycline-
and cyclophosphamide-based chemotherapy. While prior
evidence exists on AMH levels following the use of endocrine
therapy, this is the first study to our knowledge addressing
the impact on patients’ ovarian reserve of adding a taxane to
anthracycline- and cyclophosphamide-based chemotherapy and
the potential influence on treatment gonadotoxictiy of carrying
a deleterious germline BRCA mutation. In early breast cancer
patients receiving FEC chemotherapy, adding D appeared to
negatively impact on their ovarian reserve in the short-term; no
further detrimental effect was observed for endocrine therapy
use and presence of a deleterious germline BRCAmutation.
Prior studies investigating treatment impact on patients’
ovarian reserve showed that AMH decreases rapidly during the
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FIGURE 4 | The evolution of anti-mullerian hormone levels according to BRCA mutational status. AMH, anti-mullerian hormone.
first cycles of chemotherapy reaching the lowest values at the
end of systemic cytotoxic therapy (12–16). However, limited
data on AMH values beyond 1 year following chemotherapy
have been reported so far. Median AMH value at baseline
in our study (1.68 µg/L) was in line with published data
among non-cancer patients of similar age (median 2.3 µg/L)
(17). With an estimated AMH value decline of 5.6%/year
among non-cancer patients ≤40 years (17), the physiological
decline in our population would have led to a median AMH
value 3 years after diagnosis of 1.4 µg/L, which is far more
elevated than the value observed (0.17 µg/L). Thus, our findings
confirmed a deep and persistent impact of anthracycline- and
cyclophosphamide-based chemotherapy on AMH levels up to
3 years after diagnosis. In addition, the specific features of our
homogenous patient cohort provided a unique opportunity to
investigate the influence on AMH levels of adding a taxane,
using endocrine therapy as well as carrying a deleterious germline
BRCAmutation.
A sequential treatment with anthracycline- and
cyclophosphamide-based chemotherapy followed by a taxane
is the current standard (neo)adjuvant chemotherapy regimen
in young breast cancer patients (5). Despite being a widely
used regimen since many years, the gonadotoxicity of such
treatment remains controversial. While a prior meta-analysis
showed no statistically significant increased risk of amenorrhea
with the addition of a taxane (7), larger studies have recently
shown a potential negative effect (18, 19). However, limited
evidence exists on the actual and potential damage induced
by taxanes on patients’ ovarian reserve measured by AMH
levels (20). Our findings, for the first time with a clear
comparison between FEC only and FEC-D, provide some
evidence on the potential increased gonadotoxic burden
of administering a taxane following anthracycline- and
cyclophosphamide-based chemotherapy. However, partial
AMH recovery between 1 and 3 years after diagnosis was
observed for FEC-D while a further decrease was shown
for FEC only: hence, there was no difference between the
two treatment options at 3 years. Notably, the dose of
cyclophosphamide for patients treated with FEC only was
approximately twice as compared to the one received by women
who underwent FEC-D (6 vs. 3 cycles, respectively). As shown
in animal models, taxanes appear to damage specifically the
growing follicles with no apparent direct effect on primordial
follicles (21). This specific gonadotoxic mechanism may
explain our observation on the early (within 1 year) negative
impact of taxanes on AMH levels. This is in contrast with
cyclophosphamide that causes massive atresia of both primordial
and growing follicles, with subsequent longer impact on
women ovarian reserve reflected by poorer long-term AMH
recovery (22).
All young women with hormone receptor-positive breast
cancer are candidates to receive adjuvant endocrine therapy (5).
For those who are previously exposed to chemotherapy, it is
crucial to counsel them on the potential impact of this additional
treatment on their ovarian reserve. Several studies have shown
an increased risk of post-treatment amenorrhea when tamoxifen
was administered after chemotherapy (7, 18, 19). On the
contrary, the limited data on endocrine therapy gonadotoxicity
measured by AMH levels did not show any difference between
patients who received or not tamoxifen following chemotherapy
(8, 13, 16, 23). Our findings confirm the lack of detrimental effect
of endocrine therapy on patients’ ovarian reserve. Interestingly,
patients treated with tamoxifen had significantly higher AMH
levels at 1 year as compared to those who received chemotherapy
alone. Similarly, higher AMH values in patients treated with
tamoxifen following chemotherapy has been also observed
in two recent studies (8, 23), with one of them showing
a faster AMH recovery between 3 and 6 months after the
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end of systemic cytotoxic therapy for women treated with
endocrine therapy (23). Notably, when given concurrently with
chemotherapy, preclinical studies have suggested a potential
protective effect of tamoxifen against anticancer treatment
gonadotoxicity, including of cyclophosphamide-based therapy
(24). Taken together, although tamoxifen may cause perturbation
in menstrual function after chemotherapy, the available evidence
including our findings suggests the lack of detrimental effect
on patients’ ovarian reserve. Nevertheless, a proper oncofertility
counseling in these women is particularly important and should
take into account also the need to prolong such treatment up
to 10 years after diagnosis (5), with their subsequent ovarian
aging. Indeed, patients with hormone receptor-positive breast
cancer have lower chances of post-treatment pregnancies as
compared to women who are not candidates to endocrine
therapy (8, 25). An international study is currently ongoing
to investigate the safety of a temporary interruption of
endocrine therapy after 18–30 months of treatment to allow a
pregnancy (26).
More than 10% of breast cancer cases arising in young
women are hereditary tumors related to the presence of a
deleterious germline BRCA mutation (27, 28). Considering
the high mutation rate in this patient population, current
guidelines strongly support a genetic testing in all women
diagnosed at a young age irrespectively of their family history
(5). Preclinical and clinical evidence has suggested a potential
negative impact of these mutations on female reproductive
potential (29, 30). In breast cancer patients, three small
studies investigated AMH levels in BRCA-mutated breast
cancer patients but only at the time of diagnosis without
data after chemotherapy (9, 10, 31). Therefore, a major
unanswered concern in this setting is the potential increased
gonadotoxicity risk of BRCA-mutated patients (29, 30). The
only study that assessed chemotherapy-induced amenorrhea
in this setting did not show any difference between BRCA-
mutated and BRCA-negative patients (32). Our study is on the
same line suggesting for the first time the lack of detrimental
effect for carrying a deleterious germline BRCA mutation
on chemotherapy-induced gonadal damage. Further studies
in breast cancer patients with germline mutations in BRCA
or other susceptibility genes are warranted to improve their
oncofertility counseling in terms of both estimating the risk of
gonadotoxicity with the proposed anticancer treatments as well
as the efficacy and safety of fertility preservation procedures in
this setting (10, 33).
Some limitations should be considered in the interpretation
of our results. This analysis was conducted in a single center
and included a relatively small cohort of patients who received
FEC only chemotherapy or carried a deleterious germline
BRCAmutation. A few post-chemotherapy plasma samples were
missing and could not be assessed in the whole study cohort.
Data on post-treatment pregnancies and menstrual function
were not collected so that no correlation with AMH values
could be performed. Nevertheless, despite these limitations,
our study represents one of the largest AMH analyses and
with the longest follow-up conducted so far among breast
cancer patients; plasma samples were prospectively collected
at predefined timepoints during treatment and oncologic
follow-up up to 3 years after diagnosis in a homogenous
cohort of women. In addition, our study provides answers
on three relevant questions that are of crucial importance in
everyday clinical practice to properly counsel these women
on the gonadotoxicity of the proposed anticancer treatments.
Future larger prospective studies are needed to address the
clinical utility of this biomarker before its incorporation
in routine clinical practice including its potential role as
predictor of treatment-induced POI and infertility in young
cancer patients.
CONCLUSIONS
Our study confirmed the deep and prolonged adverse effect of
chemotherapy on the ovarian reserve of young breast cancer
patients with only partial recovery 3 years after treatment.
We showed that adding D following anthracycline- and
cyclophosphamide-based chemotherapy (FEC regimen)
appeared to cause an early negative impact on their
ovarian reserve. Endocrine therapy with tamoxifen and the
presence of a deleterious germline BRCA mutation did not
appear to further worsen chemotherapy gonadotoxicity.
Altogether, although future larger collaborative efforts are
needed to validate our results, we provide important data
for improving the oncofertility counseling of young breast
cancer patients.
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